PT  - JOURNAL ARTICLE
AU  - Goulenok, Tiphaine
AU  - Carvalho, Maria
AU  - Mageau, Arthur
AU  - Terrier, Benjamin
AU  - Hachulla, Eric
AU  - Papo, Thomas
AU  - Sacré, Karim
TI  - Varicella Zoster Virus Vaccination in Patients With Immune-Mediated Inflammatory Diseases: Drivers and Barriers
AID  - 10.3899/jrheum.2025-0016
DP  - 2025 Jun 01
TA  - The Journal of Rheumatology
PG  - jrheum.2025-0016
4099  - http://www.jrheum.org/content/early/2025/05/23/jrheum.2025-0016.short
4100  - http://www.jrheum.org/content/early/2025/05/23/jrheum.2025-0016.full
AB  - Patients with immune-mediated inflammatory diseases (IMIDs) undergoing immunosuppressive therapy are at increased risk of herpes zoster (HZ).1 In line with international guidelines, the French national health authority updated the vaccination strategy against varicella zoster virus (VZV) in March 2024 and now recommends that immunocompromised persons aged ≥ 18 years be vaccinated with the recombinant VZV vaccine.2-4